` DCTH (Delcath Systems Inc) vs S&P 500 Comparison - Alpha Spread

DCTH
vs
S&P 500

Over the past 12 months, DCTH has significantly outperformed S&P 500, delivering a return of 128% compared to the S&P 500's 8% growth.

Stocks Performance
DCTH vs S&P 500

Loading

Performance Gap
DCTH vs S&P 500

Loading
DCTH
S&P 500
Difference

Performance By Year
DCTH vs S&P 500

Loading
DCTH
S&P 500
Add Stock

Competitors Performance
Delcath Systems Inc vs Peers

Delcath Systems Inc
Glance View

Market Cap
398.7m USD
Industry
Health Care

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.

DCTH Intrinsic Value
12.8 USD
Undervaluation 6%
Intrinsic Value
Price
Back to Top